Subcutaneous (SC) amivantamab offers patients greater convenience, reducing administration time from hours to minutes and with a five-fold reduction in infusion-related reactions compared to the IV formulation1 European Commission (EC) approval based on positive results from the Phase 3 PALOMA-3 study1 BEERSE, Belgium — Janssen-Cilag International NV, a Johnson &...

Madrid, Spain – Cutaneous melanoma, the most aggressive form of skin cancer, is characterised by its accumulation of a large number of mutations. Although some of these alterations should be recognised as a threat by our defences, melanomas often escape immune system surveillance. As a result, more than half of...

HOUSTON, TX – A new study published in the journal Immunity reveals a mechanism that allows triple negative breast cancer (TNBC) to develop resistance to therapy. Researchers at Baylor College of Medicine showed that lipid accumulation in tumor cells and nearby immune cells promotes immune suppression, but disrupting lipid formulation reverses...